Fast Five Quiz: Confronting Obesity

Romesh Khardori, MD, PhD


September 20, 2019

In order to promote long-term weight maintenance, guidelines from the Endocrine Society recommend the use of an approved weight loss medication over not using pharmacologic therapy in patients with a BMI of ≥ 30 kg/m2 or a BMI of ≥ 27 kg/m2 and at least one associated comorbid medical condition.

The guidelines also recommend against the use of the sympathomimetic agents phentermine and diethylpropion in patients who are obese with a history of cardiovascular disease or uncontrolled hypertension. In patients with cardiovascular disease who seek pharmacologic treatment for weight loss, lorcaserin and/or orlistat are recommended.

For patients who are obese with type 2 diabetes mellitus, the guidelines recommend using antidiabetic medications that have additional actions to promote weight loss (eg, GLP-1 analogs, SGLT2 inhibitors) in addition to metformin.

Read more about the pharmacologic treatment of obesity.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.